[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@SMMT_TX Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::807103760.png) @SMMT_TX Summit Therapeutics

Summit Therapeutics posts on X about china, sig the most. They currently have XXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours.

### Engagements: XX [#](/creator/twitter::807103760/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::807103760/c:line/m:interactions.svg)

- X Week XX -XX%
- X Month XXX -XX%
- X Year XXXXX +186%

### Mentions: X [#](/creator/twitter::807103760/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::807103760/c:line/m:posts_active.svg)

- X Month X -XX%
- X Year XX +900%

### Followers: XXXXX [#](/creator/twitter::807103760/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::807103760/c:line/m:followers.svg)

- X Week XXXXX +0.13%
- X Month XXXXX +0.53%
- X Year XXXXX +25%

### CreatorRank: undefined [#](/creator/twitter::807103760/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::807103760/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[countries](/list/countries) 

**Social topic influence**
[china](/topic/china), [sig](/topic/sig)

**Top accounts mentioned or mentioned by**
[@go2forlungcancr](/creator/undefined) [@thepharmaletter](/creator/undefined)
### Top Social Posts
Top posts by engagements in the last XX hours

"OS Data from HARMONi-A Featuring Ivonescimab Plus Chemo vs. Chemo in 2L+ Treatment of Patients with EGFRm NSCLC in China to be Showcased at SITC 2025 Conducted by Akeso This Is the 1st Stat Sig OS Benefit Achieved in a Ph III Study by an Ivo Regimen"  
[X Link](https://x.com/SMMT_TX/status/1984286501442932993)  2025-10-31T15:49Z 2270 followers, XXX engagements


"Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of XXXX in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China"  
[X Link](https://x.com/SMMT_TX/status/1986885707067973919)  2025-11-07T19:57Z 2271 followers, XXX engagements